Parkin, PINK1 and mitochondrial turnover
How do parkin and PINK1 influence mitochondrial function?
Holli Kawadler, The Michael J. Fox Foundation for Parkinson's Research
07 Dec 2009
New findings published today in PNAS further support the role of PINK1 and parkin in mitochondrial quality control discussed by Dr. Chu in her post. Vives-Bauza et al. demonstrate that parkin, in a ... 
Could targeting alpha-synuclein oligomers be a novel therapeutic strategy in PD?
Hot Topics@SfN 2009
Daniela F Hernandez, Columbia
19 Oct 2009
In the poster "Secreted alpha-synuclein oligomers -- A new target for therapeutic intervention in Parkinson's Disease?, Dr. Karin Danzer et al reported that secreted alpha-synuclein oligomers are ... 
CB2 agonists, neuroprotection in MPTP model
Hot Topics@SfN 2009
Farzad Mortazavi, BUMC
18 Oct 2009
Poster Title: CB2 prevents BBB leakage and peripheral immune cell infiltration and protects nigrostriatal dopaminergic neurons in the MPTP model of Parkinson’s disease ... 
Rasagiline neuroprotective effect is consistent with loss of aldehyde and alcohol dehydrogenases in SNpc and prevention of neurotoxic DOPAL formation in sporadic Parkinson’s disease
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
Moussa Youidim, Technion
15 Oct 2009
In our transcriptomic and limited proteomic analysis of sporadic Parkinson’s disease  substantia nigra pars compacta (SNpc) (Grunblatt et al. 2004; Mandel et al. 2007) two  ... 
Neuroprotective and neurorestorative activity of Rasagiline at different dosage: What it means for ADAGIO results
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
Moussa Youidim, Technion
15 Oct 2009
I am not in a position to discuss the clinical merits of ADAGIO delayed study since I was involved in the discovery and co-development of rasagiline with TEVA. However, the discrepancy between the ... 
Rasagiline's Neuroprotective Effect Is Consistent With DOPAL Basic Research Results
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
William J. Burke, SLU
08 Oct 2009
The neuroprotective effect of rasagiline found in the ADAGIO is consistent with our research on 3,4-dihydroxyphenylacetaldehyde (DOPAL), the toxic monoamine oxidase (MAO) metabolite of dopamine ... 
Responses: 1
ADAGIO and consequences of untreated symptoms
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
Peter Schmidt, NPF
07 Oct 2009
The methodology behind the identification of disease modifying effects in the ADAGIO study is good but the implementation is questionable.  Because of intrinsic characteristics of the metrics in ... 
Clinical response as compared with a disease modifying effect - what is the cost and benefit?
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
Jeffrey N Joyce, MIHS
06 Oct 2009
As a researcher for some 25 years in Parkinson's disease, and now with oversight of clinical trials in wide-range of disciplines, some distance is helpful. First, whether or not the evidence points ... 
Response to Holford and colleagues regarding mechanistic measures in clinical trial designs
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
Brian K. Fiske, The Michael J. Fox Foundation for Parkinson's Research
02 Oct 2009
Many thanks to Drs. Holford, Nutt and Ploeger for their great analyses of the ADAGIO trial and other issues related to clinical trial design for disease modifying therapies. I hope this discussion ... 
Better ways to understand drug effects in Parkinson's disease
Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect
Nick Holford, Auckland, et al.
02 Oct 2009
This is the second reported delayed start trial with an inconclusive result. The first trial, TEMPO, was with the same drug (Parkinson Study Group, 2004a ) and since then some lessons ... 
Responses: 1